Divi's Laboratories Ltd.Margins Surge, CS Pipeline on Track

Divi's Laboratories delivered a strong Q3 FY26 with consolidated revenue growing 12.1% year-on-year to ₹2,692 crores, while operating profit before a one-time exceptional item jumped 17.6% to ₹854 crores.

A ₹74 crore non-recurring charge related to India's revised Labour Code impacted reported PAT, which came in at ₹583 crores, broadly flat year-on-year. Stripping out the exceptional item reveals robust underlying profitability growth. For nine months FY26, revenue climbed 14.8% to ₹8,081 crores and PAT grew 18.8% to ₹1,817 crores, underlining consistent execution. Gross margins improved meaningfully, with material consumption falling 350 basis points to 36.3% of sales, driven by a favourable Custom Synthesis product mix of 57% and backward integration at Kakinada Unit 3.

The company's three dedicated CS facilities are tracking toward commercial volume commencement in Calendar Q3-Q4 2027, pending customer regulatory approvals. A successful US FDA CGMP inspection at Unit 1 and a cash-rich balance sheet of ₹3,686 crores further strengthen Divi's positioning as a leading global CDMO partner.